Sri. Sunil Ghai, President Marketing, IPCA,
Sri. Supreet Deshpande, CEO, NovaLead Pharma Pvt Ltd, IPCA, Sri. Premchand
Godha, Chairman,IPCA, Sri. Ajit Jain, Managing Director, IPCA, Dr. Anil Pareek,
President Medical affairs, Clinical research and Regulatory affairs.
Mumbai, August 16, 2024: As per the
ICMR-INDIAB (2023) study, 10 crore people in India suffer from diabetes, with
an additional 13.6 crore people affected by pre-diabetes. This significant
health concern positions India to become the diabetes capital of the world by
2030.
In response to this serious healthcare
challenge, IPCA Laboratories Ltd proudly announces the launch of Diulcus, a novel
product aimed at addressing the challenges of Diabetic Foot Ulcer (DFU) in the
Indian market. Diulcus, developed by NovaLead Pharma Pvt Ltd, a pioneer in drug
repurposing, represents a significant advancement in the management of DFU. The
product has received approval from the Central Drugs Standard Control
Organization (CDSCO) and was partially funded by the Biotechnology Industry
Research Assistance Council (BIRAC), a Government of India enterprise.
The launch event was graced by esteemed
personalities, including Sri. Premchand Godha, Sri AK Jain, Dr. Anil Pareek,
Sri Sunil Ghai, and Sri. Supreet Deshpande.
During phase 3 trials in India, Diulcus
demonstrated remarkable efficacy, with a 60.3% ulcer closure rate within three
months of treatment. Remarkably, patients continued to show an ulcer closure
rate of 77.20% over six months, even after stopping treatment at three months.
These results are among the best observed for any pharmaceutical preparation
used in DFU treatment.
Mr. Premchand Godha, Executive Chairman of
IPCA Laboratories Ltd, expressed his enthusiasm about the launch, stating,
"With over 15% of diabetic patients suffering from DFU at least once in
their lifetime, DFU is the most prevalent complication caused by chronic
diabetes. The approval of this patented repurposed drug is significant because
DFU is the leading cause for lower limb amputations globally. We are delighted
to partner with NovaLead Pharma Pvt Ltd through an IP licensing arrangement to
bring Diulcus® for DFU patients in India. It demonstrates IPCA’s commitment
towards the patients suffering from unmet medical need and its focus on the
diabetes therapy."
Diulcus will be made available to the patients
of DFU by Ipca Laboratories Ltd. (Ipca) through an exclusive IP licensing arrangement
with NovaLead for Indian starting August 2024.